Actemra Side Effects: What It Treats, How It Works, and What to Watch For

Actemra side effects are often manageable but can include infections, headache, high blood pressure, injection-site reactions and changes in blood test results. Because Actemra suppresses part of the immune response, patients should understand its serious infection warnings, planned monitoring and symptoms that need medical attention.

Actemra Side Effects at a Glance

Actemra side effects may include upper respiratory infections, headache, high blood pressure, raised liver enzymes and reactions around an injection site. More serious but less common risks include severe infections, allergic reactions, low blood cell counts, liver injury and a tear in the stomach or intestine. A prescribing clinician can explain which risks are most relevant to the individual’s condition and medical history.

Actemra is the brand name for tocilizumab, a prescription biologic medicine. It affects the immune system, so it should be used with regular clinical follow-up and laboratory monitoring. Side effects differ between people and may also differ according to the condition being treated, other medicines used and whether Actemra is given by injection under the skin or infusion into a vein.

Patients should not stop, delay or alter an Actemra treatment plan on their own. If a side effect occurs, the care team can assess its likely cause, check for complications and decide whether monitoring, treatment changes or urgent care are needed.

What Actemra Treats and How It Works

Actemra blocks the action of interleukin-6, often shortened to IL-6. IL-6 is a signaling protein that helps coordinate inflammation and immune activity. In some inflammatory and immune-mediated illnesses, excessive IL-6 activity contributes to pain, swelling, tissue damage or widespread inflammation. By blocking IL-6 receptors, Actemra can reduce this inflammatory activity.

Approved uses vary by country and by formulation. In the United States, official labeling includes certain adults with rheumatoid arthritis, giant cell arteritis and systemic sclerosis-associated interstitial lung disease, as well as children with certain forms of juvenile idiopathic arthritis. It is also used in specific hospital settings for cytokine release syndrome and for eligible hospitalized patients with COVID-19 who need supplemental oxygen or breathing support and are receiving systemic corticosteroids.

Actemra does not work as a general pain reliever and is not appropriate for every type of arthritis or inflammation. The decision to use it considers disease severity, prior treatments, infection risk, laboratory results, pregnancy considerations and other health conditions. Its benefits may take time to become clear in chronic inflammatory conditions, while hospital uses follow different clinical protocols.

Common and Important Side Effects

Commonly reported Actemra side effects include cold-like upper respiratory infections, nasopharyngitis, headache, increased blood pressure and abnormal liver blood tests. People using injections under the skin may develop redness, itching, pain or swelling where the medicine was given. These local reactions are often mild, but persistent or troublesome symptoms should be discussed with the prescribing team.

Actemra can alter laboratory values even when a person feels well. It may raise liver enzymes and cholesterol levels, and it can lower neutrophils, platelets or other blood cells. These changes do not always cause symptoms at first, which is why scheduled blood tests are an important part of safe treatment.

Some side effects depend on the clinical setting. For example, people receiving Actemra for serious hospital illnesses may already be unwell and may receive several treatments at once. The treating team evaluates new symptoms and blood test changes in the context of the underlying illness rather than assuming they are caused by one medicine alone.

• Contact the care team: for persistent fever, cough, painful urination, unusual bruising, yellowing of the skin or eyes, or a worsening injection-site reaction.
• Seek urgent assessment: for trouble breathing, swelling of the face or throat, widespread hives, severe abdominal pain, black stools, vomiting blood or signs of a severe infection.

Serious Infection and Other Key Safety Warnings

Actemra has a boxed warning for serious infections. These can include bacterial, viral, fungal or other infections that may lead to hospitalization or death. Tuberculosis can develop during treatment, including reactivation of previously inactive tuberculosis, and certain fungal infections may be more likely in people who live in or have traveled to areas where these infections occur.

Before starting treatment, clinicians typically assess for active or previous infections and arrange tuberculosis testing. They may also consider hepatitis B risk and other factors based on the person’s history. Actemra should generally not be started during an active serious infection, and people who develop a serious infection while receiving it may need treatment paused while they are evaluated.

IL-6 blockade can reduce signs of inflammation, including fever and changes in C-reactive protein. This means an infection may sometimes appear less obvious than expected. Patients should therefore report feeling unwell, unusually tired, short of breath, confused, or affected by a persistent cough, skin sore, diarrhea or burning during urination, even if they do not have a high temperature.

Other important warnings include serious allergic reactions, liver problems, reductions in blood cells and gastrointestinal perforation. A perforation is a hole in the wall of the stomach or intestine and is uncommon, but urgent evaluation is needed for new severe abdominal pain, especially with fever, bowel changes, nausea or vomiting. The risk may be higher in people with diverticulitis or a history of intestinal ulcers.

Monitoring, Interactions and Vaccines

Clinicians usually arrange blood tests before Actemra is started and at intervals during treatment. Testing may include liver enzymes, neutrophil and platelet counts and cholesterol measurements. The exact schedule is individualized and depends on the condition being treated, the route of administration, other medicines and previous test results. Patients should keep laboratory appointments even when they feel well.

It is important to provide a complete list of prescription medicines, over-the-counter products, vitamins and herbal supplements. By reducing inflammation, Actemra can change the activity of certain liver enzymes that process medicines. This may affect drugs with a narrow safety range, such as warfarin, cyclosporine or theophylline, and may require monitoring or adjustments by the relevant clinician.

Using Actemra with other biologic immune-modifying treatments is generally avoided because it can increase infection risk. Corticosteroids, methotrexate and other medicines may be used in some approved treatment plans, but only under specialist direction. People should not begin an immune-suppressing treatment or use leftover medication without checking first.

Live vaccines are generally not recommended during Actemra treatment. Before starting, a clinician may review whether routine vaccinations are up to date. Inactivated vaccines may still be appropriate, but the timing and expected immune response should be discussed with the treating team. Anyone who is pregnant, planning pregnancy or breastfeeding should also discuss Actemra with a qualified clinician.

Practical Self-Care During Treatment

Good day-to-day precautions can help patients use Actemra more safely. Hand hygiene, avoiding close contact with people who have contagious illnesses when possible and seeking early advice for possible infection are sensible measures. Patients should inform every healthcare professional involved in their care that they take Actemra, including dentists, pharmacists and clinicians planning surgery or a procedure.

For people using the injectable form, the prescribing team should provide training on storage, preparation and administration. Injection sites should be rotated as directed, and injections should not be given into skin that is tender, bruised, red, hard or scarred. Questions about a missed dose, injection technique or storage should be directed to the prescribing clinician or pharmacist rather than managed by guesswork.

It can be helpful to keep a simple record of symptoms, infections, vaccination dates, laboratory appointments and all medicines. This supports more informed conversations at follow-up visits. Alcohol use and other factors that can affect the liver should be discussed honestly with the care team, particularly if liver tests become abnormal.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals can assess inflammatory conditions and medication safety needs for international patients. Care plans should always be individualized by the clinician responsible for the patient’s treatment.

When to Seek Medical Care

Patients should contact their prescribing clinician promptly if they develop possible infection symptoms, such as fever, chills, persistent cough, shortness of breath, painful urination, new diarrhea, a painful skin lesion or unusual fatigue. They should also report unexplained bruising or bleeding, yellow eyes or skin, dark urine, marked weakness, or a new rash. Early assessment is particularly important because Actemra can blunt some usual signs of inflammation.

Emergency medical care is appropriate for difficulty breathing, chest tightness, swelling of the lips, tongue or throat, fainting, widespread hives or a rapidly spreading rash. These can be signs of a serious allergic reaction. Severe or persistent abdominal pain, especially when accompanied by fever, vomiting or a change in bowel habits, also needs urgent evaluation.

A person should not take the next dose until they have received advice if they are being assessed for a serious infection or severe reaction. However, routine changes to treatment should be made only with the prescribing team. For questions about an individual dose, timing or missed dose, the safest step is to contact the clinician or pharmacist who manages the prescription.

Frequently asked questions

What are the most common Actemra side effects?

Common Actemra side effects include upper respiratory infections, headache, increased blood pressure, raised liver enzymes and injection-site reactions. The likelihood of a particular side effect can vary by the treated condition and whether the medicine is given under the skin or into a vein. Blood test changes may occur without noticeable symptoms.

Can Actemra increase the risk of infection?

Yes. Actemra can lower the body’s ability to fight some infections and carries an important warning about serious infections, including tuberculosis. Patients should contact their clinician promptly if they develop symptoms of infection or feel unwell in an unusual way.

Does Actemra affect liver tests or cholesterol?

Actemra can increase liver enzyme levels and cholesterol levels. It can also affect blood cell counts. Clinicians arrange blood tests before and during treatment to identify changes early and determine whether any action is needed.

Can patients receive vaccines while taking Actemra?

Live vaccines are generally avoided during Actemra treatment because the immune system is being modified. Other vaccines may be suitable, but their timing should be reviewed with the prescribing clinician. Patients should not postpone or receive vaccines without discussing their treatment plan.

What medicines can interact with Actemra?

Actemra may change how the body processes some medicines, including certain drugs that need careful blood-level or effect monitoring. It is also generally not combined with other biologic immune-modifying medicines because of infection risk. A pharmacist or clinician should review all prescription medicines, supplements and nonprescription products.

Should Actemra be stopped before surgery or during an infection?

The answer depends on the procedure, the underlying condition and the person’s infection risk. Clinicians may advise holding treatment around some surgeries or during a serious infection, but patients should not make that decision alone. The prescribing specialist and surgical team should coordinate the plan.

References

• U.S. Food and Drug Administration
• Genentech Actemra Prescribing Information
• National Institute of Arthritis and Musculoskeletal and Skin Diseases
• Centers for Disease Control and Prevention
• American College of Rheumatology

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.